 Skye Bioscience Inc OTCQB:SKYE has announced that the shareholders of Emerald Health Therapeutics Inc CSE:EMH, OTCQX:EMHTF have approved the proposed plan of arrangement which will result in the integration of the two companies, and also revealed regulatory approval to begin its first-in-human Phase 1 clinical study. The pharma company said Emerald will now seek a final order from the Supreme Court of British Columbia to approve the arrangement. 